JP2024500786A5 - - Google Patents

Info

Publication number
JP2024500786A5
JP2024500786A5 JP2023537130A JP2023537130A JP2024500786A5 JP 2024500786 A5 JP2024500786 A5 JP 2024500786A5 JP 2023537130 A JP2023537130 A JP 2023537130A JP 2023537130 A JP2023537130 A JP 2023537130A JP 2024500786 A5 JP2024500786 A5 JP 2024500786A5
Authority
JP
Japan
Prior art keywords
aav
sequence
construct
itr
utr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537130A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024500786A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/064924 external-priority patent/WO2022146839A1/en
Publication of JP2024500786A publication Critical patent/JP2024500786A/ja
Publication of JP2024500786A5 publication Critical patent/JP2024500786A5/ja
Pending legal-status Critical Current

Links

JP2023537130A 2020-12-29 2021-12-22 Clrn1関連難聴及び/または視力低下を治療するための組成物及び方法 Pending JP2024500786A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063131413P 2020-12-29 2020-12-29
US63/131,413 2020-12-29
PCT/US2021/064924 WO2022146839A1 (en) 2020-12-29 2021-12-22 Compositions and methods for treating clrn1-associated hearing loss and/or vision loss

Publications (2)

Publication Number Publication Date
JP2024500786A JP2024500786A (ja) 2024-01-10
JP2024500786A5 true JP2024500786A5 (enExample) 2024-12-27

Family

ID=80050943

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537130A Pending JP2024500786A (ja) 2020-12-29 2021-12-22 Clrn1関連難聴及び/または視力低下を治療するための組成物及び方法

Country Status (16)

Country Link
US (1) US20240139344A1 (enExample)
EP (1) EP4271419A1 (enExample)
JP (1) JP2024500786A (enExample)
KR (1) KR20230127263A (enExample)
CN (1) CN117157108A (enExample)
AU (1) AU2021412962A1 (enExample)
CA (1) CA3203373A1 (enExample)
CL (1) CL2023001896A1 (enExample)
CO (1) CO2023007325A2 (enExample)
DO (2) DOP2023000132A (enExample)
EC (1) ECSP23057004A (enExample)
IL (1) IL304006A (enExample)
JO (1) JOP20230151A1 (enExample)
MX (1) MX2023007800A (enExample)
PE (1) PE20240012A1 (enExample)
WO (1) WO2022146839A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250059407A (ko) * 2022-08-05 2025-05-02 데시벨 테라퓨틱스, 인크. Slc26a4 조절 요소 및 이의 용도
CN120285151B (zh) * 2025-04-14 2026-03-31 山东第一医科大学(山东省医学科学院) HuR及其编码基因在制备治疗老年性耳聋药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5869305A (en) 1992-12-04 1999-02-09 The University Of Pittsburgh Recombinant viral vector system
US6204059B1 (en) 1994-06-30 2001-03-20 University Of Pittsburgh AAV capsid vehicles for molecular transfer
US5741683A (en) 1995-06-07 1998-04-21 The Research Foundation Of State University Of New York In vitro packaging of adeno-associated virus DNA
US6093570A (en) 1995-06-07 2000-07-25 The University Of North Carolina At Chapel Hill Helper virus-free AAV production
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
CA2264482A1 (en) 1996-09-06 1998-03-12 The Trustees Of The University Of Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase
EP1007637B1 (en) 1997-04-14 2004-06-30 Cell Genesys, Inc. Methods for increasing the efficiency of recombinant aav product
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US6146874A (en) 1998-05-27 2000-11-14 University Of Florida Method of preparing recombinant adeno-associated virus compositions
EP1135468B1 (en) 1998-11-10 2010-01-06 University Of North Carolina At Chapel Hill Virus vectors and methods of making and administering the same
AU6814901A (en) 2000-06-01 2001-12-11 Univ North Carolina Methods and compounds for controlled release of recombinant parvovirus vectors
CA2448066A1 (en) 2001-05-31 2002-12-12 Chiron Corporation Chimeric alphavirus replicon particles
WO2003023026A1 (en) 2001-09-06 2003-03-20 Alphavax, Inc. Alphavirus replicon vector systems
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
AU2003274397A1 (en) 2002-06-05 2003-12-22 University Of Florida Production of pseudotyped recombinant aav virions
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
US7557197B2 (en) 2004-01-28 2009-07-07 Oregon Health & Science University Human soluble neuropilin-1 primary polyadenylation signal and uses thereof
WO2006012414A2 (en) 2004-07-20 2006-02-02 Critical Therapeutics, Inc. Novel polyadenylation signal for use in expression vectors
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
AU2010316982B2 (en) * 2009-11-09 2013-09-12 Genepod Therapeutics Ab Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
JP2015527296A (ja) 2012-03-26 2015-09-17 アメリカ合衆国 哺乳動物細胞へのパッケージングされたrnaの新規の送達
US9163259B2 (en) * 2012-05-04 2015-10-20 Novartis Ag Viral vectors for the treatment of retinal dystrophy
GB201518979D0 (en) 2015-10-27 2015-12-09 Univ Leuven Kath Treatment of hepatic steatosis related oligo-ovulation
EP3474941A1 (en) 2016-06-22 2019-05-01 The Charles Stark Draper Laboratory, Inc. A system for inner ear drug delivery via trans-round window membrane injection
WO2018039375A1 (en) 2016-08-23 2018-03-01 Akouos, Inc. Compositions and methods for treating non-age-associated hearing impairment in a human subject
WO2019084145A1 (en) 2017-10-25 2019-05-02 The Charles Stark Draper Laboratory Inc. APPARATUS AND METHOD FOR DRUG DELIVERY ACROSS THE ROUND WINDOW MEMBRANE
IL325122A (en) 2018-02-22 2026-02-01 Akouos Inc Compositions and methods for treating non-age-related hearing impairment in humans
WO2019200016A1 (en) * 2018-04-10 2019-10-17 President And Fellows Of Harvard College Aav vectors encoding clarin-1 or gjb2 and uses thereof
BR112020026606A2 (pt) * 2018-06-25 2021-04-06 Akouos, Inc. Métodos de tratamento de perda auditiva e/ou perda de visão associada à clrn1
CN113853437A (zh) 2018-11-07 2021-12-28 阿库斯股份有限公司 腺相关病毒载体用于在内耳中的毛细胞和支持细胞中校正基因缺陷/表达蛋白质的用途
WO2021242926A1 (en) 2020-05-27 2021-12-02 Akouos, Inc. Devices, systems, and methods for delivering fluid to the inner ear

Similar Documents

Publication Publication Date Title
JP2026027271A5 (enExample)
ES2859605T3 (es) Procedimientos y composiciones para tratar enfermedades del cerebro
ES2264123T3 (es) Adenovirus recombinantes defectivos para la terapia genica de tumores.
JP2022500066A5 (enExample)
JP2023503637A5 (enExample)
JP2021519583A5 (enExample)
US20220193207A1 (en) Compositions useful for treatment of pompe disease
JP2024513949A5 (enExample)
JP2020518268A5 (enExample)
RU2019139555A (ru) Генная терапия нейрональных цероидных липофусцинозов
JP2022106918A5 (enExample)
RU2020137429A (ru) Лечение пигментного ретинита
JP2023524291A5 (enExample)
EP4527933A1 (en) Dual-carrier system for treating hearing damage, and use thereof
JP2022553406A5 (enExample)
CN106794262A (zh) 哺乳动物rpe65的高异构水解酶活性突变体
CA3173768A1 (en) Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
JP2022530095A5 (enExample)
JP2023542279A5 (enExample)
JP2021525531A5 (enExample)
JP2021533801A5 (enExample)
JP2023040219A5 (enExample)
Lundstrom Gene therapy cargoes based on viral vector delivery
JP2021531044A5 (enExample)
JP2024545186A5 (enExample)